11 June 1999
Perioperative Single High Dose ATG-Fresenius S Administration as Induction Immunosuppressive Therapy in Cadaveric Renal Transplantation- Preliminary Results
Radoslaw Samsel, Andrzej Chmura, Zbigniew Wlodarczyk, Janusz Wyzgal, Tomasz Cieciura, Jacek Pliszczynski, Grazyna Korczak, Tomasz Lazowski, Leszek Paczek, Janusz Walaszewski, Mieczyslaw Lao, Wojciech RowinskiAnn Transplant 1999; 4(2): 37-39 :: ID: 497453
Abstract
Monoclonal and polyclonal antilymphocyte antibodies have been used successfully in organ transplantation as induction therapy and in the treatment of acute graft rejection. Used for induction the medication is generally given for the first 7-10 days. The aim of this study was to assess the safety and efficacy of single high dose (9 mg/kg) ATG Fresenius Sgiven perioperatively, before revascularization, to kidney allograft recipients. During last twelve months seventy six, first cadaveric kidney adult recipients were included into the study in two centers (center A-64, center 8-12). All patients received triple drug immunosuppression(Neoral. steroids and Cellcept which was replaced by azathioprine after 4 months). and were randomized to receive ATG or not. The follow-up period ranged from I month up to I year. The preliminary results are very promising. the rejection rate in bolus group was significantly lower than in control. No significant side effects or serious adverse events in both groups were observed.
Keywords: Atg, Kidney Transplantation, Immunosuppression, inductiontherapy
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860